Bornyl cis-4-hydroxycinnamate treatment inhibited p-JNK, p-Jun, p-p38, and p-ERK protein expression, indicating that the MAPKs signaling pathway is involved in the inhibitory effect of bornyl cis-4-hydroxycinnamate in malignant melanoma cells. Here, JUN is linked to melanoma.